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Abstract: Heparin and heparan sulfate represent key members of the glycosaminoglycan family
of carbohydrates and underpin considerable repertoires of biological importance. As such, their
efficiency of synthesis represents a key requirement, to further understand and exploit the H/HS
structure-to-biological function axis. In this review we focus on chemical approaches to and
methodology improvements for the synthesis of these essential sugars (from 2015 onwards). We
first consider advances in accessing the heparin-derived pentasaccharide anticoagulant fondapar-
inux. This is followed by heparan sulfate targets, including key building block synthesis,
oligosaccharide construction and chemical sulfation techniques. We end with a consideration of
technological improvements to traditional, solution-phase synthesis approaches that are
increasingly being utilised.
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1. Introduction
Carbohydrates are indispensable to glycoconjugate biological
function; this is typified by the glycosaminoglycans (GAGs).
GAGs are present on most animal cell surfaces and in the
surrounding extracellular matrix. They are extremely diverse,
containing a linear and structurally heterogeneous anionic
glycan chain and impart important biological functions by
binding to different growth factors, enzymes, morphogens, cell
adhesion molecules, and cytokines. One GAG in particular,
heparan sulfate (HS) is involved in mediating mammalian cell
function, exemplified by its interaction with growth factors
such as fibroblast growth factors (FGFs), a protein family
involved in cell proliferation, differentiation, and
angiogenesis.[1] HS also mediates many pathological conditions
including cancer,[2] Alzheimer’s disease,[3] viral infections such
as SARS-Cov-2,[4,5] HIV[6] and HSV,[7] alongside numerous
bacterial infectivity events.[8] Structurally related to HS is the
anticoagulant heparin (H), present within mast cells and
considered a highly sulfated, tissue-specific variant of HS.
The chemical structures of H and HS (Figure 1) consist of
repeating disaccharide units, composed of glucosamine (d-
GlcN) and a uronic acid (d-GlcA). Its microstructure is
diverse: the amino sugar can be N-sulfated (d-GlcNS) or N-
acetylated (d-GlcNAc), d-GlcA can be epimerised to l-IdoA
and saccharide units are variably substituted with O-sulfate
groups, at the C6 (and occasionally C3) of d-GlcN and at C2
of d-GlcA/l-IdoA. HS chains have an average molecular
weight of 30 kDa and this, taken in context with the
possibilities for functional group variation, presents a huge
structural microheterogeneity and enormous scientific chal-
lenge in unravelling and understanding the HS structure-to-
function paradigm.
Due to their structural complexity and biological impor-
tance, the synthetic challenge surrounding access to (and
application of) structurally defined H and HS fragments is
significant and of continued interest. In this review we focus
on chemical approaches to and methodology improvements
for the synthesis of H/HS from 2015 onwards. Contextually,
this should be considered alongside the impressive and
complimentary advances in chemoenzymatic approaches to
access H/HS that have been well reviewed elsewhere,[9,10]
alongside GAG synthesis approaches in general.[11] We first
consider advances towards the synthesis of the heparin
pentasaccharide fondaparinux (and analogues), followed by HS
targets, including building block synthesis, oligosaccharide
construction and chemical sulfation methods. We end with a
consideration of technological improvements to traditional,
solution-phase synthesis approaches that are increasingly being
utilised.
2. Developments in the Chemical Synthesis of
Heparin-Related Pentasaccharide Sequences
Synthesis of the pentasaccharide anticoagulant drug fondapar-
inux 1 (Arixtra) by Sanofi and Organon in 2001 represented a
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Figure 1. Overview of HS structure, heteroatoms commonly sulfated are
shown in magenta (d-GlcN- and -O6 shown), C5 epimeric uronates green.
Included within the blue box is the major repeating disaccharide unit of
structurally related H. Free acid form shown.
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landmark achievement in the construction of mimetic heparin
oligosaccharide sequences.[12] However, the original 50-step
route delivered the target molecule in an overall yield of only
0.1%, presenting an opportunity and requirement for
efficiency improvements. We first discuss recent efforts to
develop more efficient synthetic routes to 1 using traditional
modular synthetic routes and then explore one-pot, program-
mable methodologies.[13]
2.1. Improving Large-Scale Synthesis of 1
In 2017, Ding and co-workers’ reported a practical and
efficient large-scale synthesis of 1 using a combination of the
Alchemia and Sanofi protocols (Scheme 1).[14] The group
identified that the original Alchemia protocol involved simple
and practical access to the monosaccharide building blocks
2–3 and, therefrom, trisaccharide donor 6 on a large scale.
However, a drawback in the glycosidation of 6 with
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disaccharide acceptor 7 (to give pentasaccharide 8) was delivery
of the desired material in very poor yield. This was suggested
to arise from the use of acid labile PMB protecting groups
within 6. Comparatively, in the case of the Sanofi protocol,
glycosylation of acceptor 12 with trisaccharide 11 was
successful and observed with excellent diastereoselectivity in
delivering pentasaccharide 13. However, the use Cerny
epoxide precursors 9 or 10 were not amenable to large scale
application, due to stability issues.
Based on these observations, the group decided to adopt
the Alchemia method to access trisaccharide donor 6 for
subsequent glycosylation using the Sanofi method (Scheme 2).
The acid labile PMB groups within trisaccharide donor 6 were
replaced with acetyl groups to provide trisaccharide 14.
Retaining the use of thioglycoside donors, trisaccharide 14 was
successfully coupled with disaccharide acceptor 7 to deliver
pentasaccharide 15 in 74% yield and on >100 g scale.
Pentasaccharide 15 was converted through to 1 in 5 steps in
62% overall yield and on an impressive >30 g scale.
2.2. Iterative One-Pot Syntheses of 1
In 2018, Wong and co-workers’ reported a highly efficient and
programmable one-pot method for the synthesis of protected
Scheme 1. Overview and issues surrounding Alchemia (left-hand box) and Sanofi (right-hand box) strategies towards the synthesis of 1.
Scheme 2. Ding and co-workers’ strategy to synthesise 1 combining aspects of the Alchemia and Sanofi methods. Reagents and conditions: (a) (i) DDQ, CH2Cl2,
H2O (10 :1), 0–20 °C, 83%, or (ii) CAN CH3CN, H2O (20 :1), 0 °C, 76%, or (iii) CF3CO2H, CH2Cl2 (1 : 10), 0 °C, 73%; (b) (i) Ac2O, pyridine, 20 °C, 2 h,
92%, or (ii) Ac2O, Na2CO3, 20 °C, 10 h, 84%; (c) NIS, CF3SO2OH, CH2Cl2, 4 Å MS,   20 °C, 3 h, 74%; (d) NaOH, THF, 0 °C, 24 h, 97%;
(e) SO3 ·pyridine, pyridine, Et3N (5 :1), 20 °C, 83%; (f) PMe3, NaOH, THF; (g) SO3 ·pyridine, pyridine, Et3N (5 :1), 20 °C, 93%, 2 steps; (h) H2, Pd/C,
MeOH, H2O (1 :1), 83%.
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heparin pentasaccharides utilising thioglycoside building
blocks (Scheme 3).[15] The group designed eighteen key
intermediates with improved relative reaction values (RRVs)
for a one-pot synthesis to then access 6-O sulfation pattern
variant pentasaccharides.
The building blocks were designed to incorporate the
following (a) highly stereoselective α-glycosylation outcomes,
influenced by ring protecting groups (N3, TBDPS, and Ac)
(b) use of TBDPS as a protecting group at the d-GlcN-O-6
position to increase the RRV of donor 16[16] (c) stereoselective
construction of β-1,4-glycosidic linkages using a neighbouring
C2-O-benzoyl ester and (d) selective installation of a 6-O-
sulfate using orthogonal acetyl and levulinic protecting groups.
To investigate if it was better to introduce the glucuronic acid
as part of the disaccharide building block or through oxidation
at the pentasaccharide level, 17b (RRV=38.2) was chosen as
the thioglycoside donor to be used in the one-pot synthesis of
pentasaccharide 19e. This material was subsequently depro-
tected, oxidised and esterified to generate pentasaccharide 19a
in 42% yield. In contrast, when glucuronic acid containing
disaccharide acceptor 17a (RRV=18.2) was used, pentasac-
charide 19a was furnished in 54% yield (Scheme 3). Thus, it
was concluded here that the pre-glycosylation oxidation was
more efficient than a post-glycosylation oxidation (54% versus
42% yields respectively).
Following the successful synthesis of pentasaccharides
19a–d, 19a and 19b were further used to obtain regiodefined
sulfate derivatives 22 and 26 (Scheme 4). Notably, when
introducing O-sulfates, the group found it crucial to first
replace the d-GlcN-O-6-TBDPS group in 19a/b with a benzyl
group (20a/b), to prevent an unwanted insertion of SO3 into
the Si  O bond. It was also noted that co-solvent-promoted O-
benzylation using Ag2O/BnBr in nHex :CH2Cl2 was found to
be an ideal method to avoid acyl migration, ester hydrolysis
and sugar decomposition.[17]
Recently, Zhao and co-workers’ also developed an opti-
mised route towards 1, harnessing a preactivation-based, one-
pot glycosylation, concomitantly installing two new stereo-
centres with exclusive α-stereoselectivity (Scheme 5).[18] To
synthesise pentasaccharide precursor 30, monosaccharide thio-
glycoside donor 27 and disaccharide acceptors 28 and 29 were
glycosylated in one-pot using p-TolSCl and AgOTf as
promotors, delivering 30 in 37% yield. The target compound
1 was obtained following saponification, O-sulfation, hydro-
genolysis and N-sulfation. The total number of synthetic steps
was 34, from commercial materials, and the overall yield was
27%; notably demonstrating a simplified route to 1 with
improved synthetic efficiency.
Most recently, Wong and co-workers’ reported a poten-
tially scalable and programmable one-pot synthesis of 1 using a
[1,2,2] strategy (Scheme 6).[19] This synthesis built on an
earlier approach by the group accessing the related anti-
coagulant drug idraparinux.[20] The building blocks were
designed with TBDPS and acetyl at the 6-O positions to
support α-selective glycosylation. Initial glycosylations using
disaccharide acceptor 32a (R=Bz, Scheme 6) gave a poor yield
of 26%, however upon switching to acceptor 32b (R=Ac,
Scheme 6), an improved yield of 50% was achieved. The total
synthesis of 1 was achieved in 4.2% yield over a total of
22 linear steps.
Scheme 3. Wong and co-workers’, programmable one-pot synthesis of pentasaccharides 19a–d. Reagents and conditions: (a) NIS, TfOH, CH2Cl2,   45 to
  25 °C, 19a: 54%, 19b: 48%, 19c: 50%, 19d: 42%; (b) (i) DDQ, CH2Cl2, H2O (10 :1), rt, 1 h; (ii) BAIB, TEMPO, CH2Cl2, H2O (2 :1), rt, 2 h; (iii) MeI,
KHCO3, DMF, 0 °C to rt, 4 h, 42%, 3 steps.
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3. Synthetic Methodology Developments for
Heparan Sulfate Synthesis
At a basic level, HS consists of a repeating disaccharide unit of
either (-l-IdoA-α-1,4-d-GlcN-α-1,4-) or (-d-GlcA-β-1,4-d-
GlcN-α-1,4-). Consequently, efforts in HS synthesis usually
focus first on the provision of appropriate disaccharide
building blocks,[21] for subsequent iterative oligosaccharide
assembly. Additionally, de novo syntheses of mimetic fragments
containing just one monosaccharide component (e. g., l-IdoA)
have been completed.[22] With appropriately protected oligo-
saccharide sequences in hand, final functionalisations are made
to incorporate essential O- and N-sulfate groups. Accordingly,
we have divided recent accomplishments adopting this
approach into three categories: i) synthesis of HS building
blocks ii) oligosaccharide synthesis and iii) concepts to effect
O- and N-sulfation.
3.1. Synthesis of HS Building Blocks
3.1.1. HS Building Blocks from Polysaccharide Digestion
Hsieh-Wilson and co-workers’ have recently described novel
access to key HS disaccharide building blocks 35a–d
(Scheme 7).[23] Notably, two of the four core disaccharides
generally required for HS assembly were obtained via digestion
Scheme 4. Wong and co-workers’, diversification of pentasaccharides to access regiodefined, sulfated derivatives. Reagents and conditions: (a) HF ·pyridine,
pyridine, 0 °C to rt, 12 h; (b) BnBr, Ag2O, nHex, CH2Cl2 (4 : 1), 4 Å MS, 70 °C, 12 h, 20a: 68% 2 steps, 20b: 66% 2 steps, 24: 81%; (c) (i) LiOH, H2O2,
THF,   5 °C to rt, 8 h; (ii) NaOH, MeOH, rt, 18 h; (iii) SO3 ·Et3N, DMF, 55 °C, 12 h; (d) (i) H2, Pd(OH)2/C, MeOH, 36 h, rt; (ii) SO3 ·pyridine, NaOH,
pH 9.5, H2O, rt, 38 h; 22: 40% 5 steps, 26: 47% 5 steps; (e) NH2NH2 ·AcOH, THF, MeOH (1 :1), 0 °C to rt, 2 h, 23: 85%.
Scheme 5. Zhao and co-workers’ preactivation-based one-pot synthesis of 1. Reagents and conditions: (a) p-TolSCl, AgOTf,   78 to   20 °C, 1 h per
glycosylation, 37%; (b) LiOH, H2O2, THF; (c) NaOH, MeOH, 81%, 2 steps; (d) SO3 ·Et3N, DMF, 65 °C, 24 h, 94%; (e) H2, Pd/C, MeOH, H2O;
(f) SO3 ·pyridine, NaOH, H2O, rt, 97%.
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of readily available natural polysaccharides, enabling a cost-
effective and scalable entry to such materials. Firstly, heparin
was hydrolysed to a crude disaccharide using 2 M TfOH at
100 °C, followed by carboxylate esterification and O/N-
acetylation in one pot to afford the core d-GlcN-l-IdoA
disaccharide 35a in 18% yield over 4 steps. Importantly, the
method alleviated any requirement for effective 1,2-cis glyco-
sylation in generating a d-GlcN-α-1,4-l-IdoA building block.
Secondly, heparosan was selectively digested at the d-GlcN
reducing position within the polysaccharide, thus accessing a
related d-GlcA-d-GlcN disaccharide 35b in 16% yield over
four steps and with reaction conditions identical to those used
for 35a, save for a reduced molarity of TfOH. Two further
core HS disaccharides, 35c (d-GlcN-d-GlcA) and 35d (l-
IdoA-d-GlcN), could also be obtained through uronate C5
epimerisation of 35a and 35b respectively (Scheme 7).
The authors were also able to access more complex,
orthogonally protected disaccharide building blocks, exempli-
fied by 37, in just nine steps from heparin (Scheme 8).
Disaccharide 37 then underwent strategic protecting group
manipulations to afford both donor 38 and acceptor 39
components. These were then combined to access tetrasacchar-
ide 40 in a 60% yield (Scheme 8). The incorporation of seven
different protecting groups into 40 uniquely allowed each l-
IdoA-2-O, d-GlcN-6-O and N- to be unmasked for regiose-
lective sulfation.
3.1.2. Hexynylbenzoate Donors for α-Selective
Glycosylation
Commonly, the construction of d-GlcN-α-1,4-d-GlcA/l-IdoA
linkages involves the use of 2-azido-2-deoxy-glucopyranoside
donors with thioglycoside or imidate as the preferred leaving
group. In 2015 Yu and co-workers’ reported using ortho-
hexynylbenzoate donors of type 41 for the successful synthesis
of d-GlcN-α-1,4-d-GlcA/l-IdoA linkages under Au(I) catalysis
Scheme 6. Wong and co-workers’ programmable one-pot synthesis of 1. Reagents and conditions: (a) NIS, TfOH, CH2Cl2,   45 to   25 °C, 3 h, 33a: 26%,
33b: 50%; (b) HF ·pyridine, pyridine, 0 °C to rt, 16 h, 34a: 89%, 34b: 91%; (c) (i) LiOH, H2O2, THF,   5 °C to rt, 16 h then NaOH, MeOH, 0 °C to rt,
18 h; (ii) SO3 ·Et3N, DMF, 55 °C, 16 h; (iii) H2, Pd(OH)2, MeOH, pH 7, 36 h; (iv) SO3 ·pyridine, NaOH, H2O, 48 h, 67%, 4 steps. For acceptors 32a–b, no
anomeric leaving group is present hence RRVs were not measured and assigned as zero.
Scheme 7. Hsieh-Wilson’s synthesis of four core heparan sulfate disaccharides. Reagents and conditions (a) 1 or 2 M TfOH, H2O, 100 °C; (b) AcCl, MeOH,
65 °C; (c) Ac2O; (d) Ac2O, pyridine, 35a: 18%, 4 steps, 35b: 16%, 4 steps; (e) NBS, CCl4, hν, reflux, 36a: 80%, 36b: 75%; (f) Bu3SnH, AIBN, toluene,
110 °C, 33%; (g) Bu3SnH, Et3B, toluene, 20 °C, 63%.
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(Scheme 9).[24] The optimised reaction conditions used
Ph3PAuCl/AgOTf and a donor/acceptor ratio of 3 :1. Given
the known low reactivity of uronate d-GlcA/l-IdoA acceptors,
high levels (3.0 equiv.) of donor were used to deliver high
yields. A range of armed/disarmed donors and acceptors were
screened (22 examples). Overall, the reaction yields were high
(85–99%), but donor/acceptor reactivity and donor O-6
protecting group identity had a significant effect on the
stereoselectivity. Reactive donors/acceptors gave poorer α-
selectivity (43a versus. 43c) and an ester at O-6 improved α-
selectivity, suggested to be due to long range participation of
such groups (43a versus. 43b). [2+2] glycosylations to access
tetrasaccharides showed an l-IdoA acceptor outperform its d-
GlcA counterpart in terms of yield and α-selectivity (43d
versus 43e).
3.1.3. Programming for Regiodefined HS O/N Sulfation
In 2015, Huang and co-workers’ assembled seven hexasacchar-
ides with different sulfation patterns to demonstrate sequence
diversity. These materials originated from a single hexasacchar-
ide precursor 47 (Scheme 10).[25]
To synthesise hexasaccharide precursor 47, disaccharide
thioglycoside donor 44 and disaccharide acceptors 45 and 46
were glycosylated in one-pot using p-TolSCl and AgOTf as
promotors, delivering 47 in 67% yield. Following Lev-
deprotection at C6 of idose, 47 was oxidised to uronate ester
48. Next, the authors found it necessary to replace the non-
reducing end O4-TBDMS group with Bn, prior to sulfation,
to deliver 49. Hexosamine nitrogen was unmasked, following
azide reduction with 1,3-propanedithiol and the remaining
deprotections and O/N-sulfations were completed chemically
and enzymatically (chemical steps shown in Scheme 10) to
provide a panel of hexasaccharides 51a–d.
Gardiner and co-workers’ also reported a synthetic
approach to a small matrix of protected heparin-type
oligosaccharides containing orthogonal d-GlcN O-6 protecting
groups.[26] Building on their earlier work,[27–30] this was
completed to demonstrate capability in accessing programm-
ability at specific sites, relevant to sulfation or other
Scheme 8. Synthesis of universal tetrasaccharide building block 40. Reagents and conditions: (a) NaOMe, MeOH; (b) LevOH, EDC, DMAP, DCM, 91%
2 steps; (c) p-TsOH, MeOH; (d) TBDPSCl, imidazole, DCM, 86% 2 steps; (e) BzCl, pyridine, 95%; (f) CH2(CH2SH)2, Et3N, Pyridine, H2O; (g) TFAA,
pyridine, 81% 2 steps; (h) HOCH2CO2tBu, NIS, AgOTf, DCM, 82%; (i) NaOMe, MeOH, DCM, 89%; (j) FmocCl, pyridine, 90%; (k) TFA, Et3SiH, DCM,
72%; (l) NIS, AgOTf, DCM, RT, 60%.
Scheme 9. Yu and co-workers’ Au catalysed synthesis of α-d-GlcN-(1!4)-d-GlcA/l-IdoA glycosidic linkages.
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modifications. Capability was demonstrated through the
choice of d-GlcN 6-OH protecting group used; OBn or OAc
programmed the fate of d-GlcN O-6 (OBn to deliver 6-OH
and OAc for 6-OS).
In 2018, Boons and co-workers’ reported an enzymatic
modification of three chemically synthesised hexasaccharides,
harnessing a d-GlcN-6-OMe blocking group, to effect
regiodefined enzymatic modification and provide a library of
21 hexasaccharides.[31]
3.1.4. An S-Linked HS Disaccharide
In comparison to O-glycosides, S-glycosides can show im-
proved stability towards hydrolytic enzymes.[32] Kovensky and
co-workers’ reported the synthesis of an S-glycoside analogue
of the disaccharide unit of HS and prepared multivalent
glycoclusters based around this unit (Scheme 11).[33] The
authors opted to use d-Glc instead of d-GlcN, as previous
studies showed that such a substitution made only a small
difference to biological activity.[34] Initial attempts to synthesise
56 using donors 52a–b and acceptor 53 gave only trace
amounts of the desired product. However, switching the
approach to synthesise 56 through nucleophilic substitution of
4-O-triflated galactoside 55 with glycosyl thiol 54 afforded the
desired S-glycoside in 79% yield (α/β, 12 :82).
3.2. Synthesis of Di- and Oligosaccharide HS Sequences
3.2.1. Iterative, Reducing End HS Oligosaccharide
Synthesis
Gardiner and co-workers’ described a novel approach towards
the preparation of protected HS oligosaccharides bearing
reducing end thioglycoside functionality (Scheme 12).[35] The
authors employed a sequential chemoselective glycosylation at
the reducing end, additive to their previously reported non-
reducing terminus extension via lactone-terminated d-GlcN-l-
IdoA intermediates.[36] This new approach introduced chemo-
selective activation of a reducing end l-IdoA-lactone to enable
iterative HS oligosaccharide synthesis, without the need to
interconvert the reducing end anomeric group.
Glycosylation of lactone thioglycoside acceptor 58 with
GlcN donor 57 gave an intermediate disaccharide lactone
which, upon subsequent opening and protection, afforded
Scheme 10. Preactivation-based one-pot synthesis of hexasaccharide 47 to access differentially sulfated HS sequences. Reagents and conditions: (a) p-TolSCl,
AgOTf,   78 °C, then 45 or 46, TTBP,   30 °C, 1 h per glycosylation, 67%; (b) NH2NH2 ·AcOH, pyridine, 0 °C, then BAIB, TEMPO, CH2Cl2, H2O (2 :1),
rt, then MeI, K2CO3, DMF, rt, 70%, 3 steps; (c) HF ·pyridine, pyridine, 94%; (d) BnBr, Ag2O, 50%; (e) MeONa; (f) 1,3-propanedithiol, Et3N, 76% 2 steps;
(g) SO3 ·pyridine, pyridine, 55 °C; (h) H2, Pd(OH)2, then LiOH, H2O2, 51a: 72%, 3 steps; (i) (a) Ac2O, TEA; (b) H2, Pd(OH)2; (c) LiOH, H2O2, 51b: 54%,
4 steps; (j) SO3 ·pyridine, pyridine, 55 °C; (k) H2, Pd(OH)2, then LiOH, H2O2, 51c: 63%, 3 steps; (l) (a) LiOH, H2O2, then KOH; (b) PMe3, NaOH;
(c) SO3 ·NEt3, NaOH, CH3OH, rt; (d) H2, Pd(OH)2, 65%, 4 steps.
Scheme 11. Synthesis of S-glycosidic analogue of disaccharide unit of HS. Reagents and conditions: (a) TMSOTf, CH2Cl2,   60 to 0 °C or Ag2CO3, AgOTf or
HgO, HgBr2; (b) Et3N, DMF, DTT,   60 °C, 20 h, 79%.
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thioglycoside donor 60 in 67% yield over 3 steps. Acceptor 61
was prepared by glycosylation of 4-O-trichloroacetyl-protected
glucoazide donor 59 and 58 to provide an intermediate
disaccharide. From this the 4-O-trichloroacetyl group was
removed to afford acceptor 61 in a 77% yield. Oligosaccharide
assembly began with glycosylation of acceptor 61 using donor
60 to afford tetrasaccharide 62a in 85% yield. Subsequent
methanolysis and benzoylation of 62a afforded tetrasaccharide
63a in near quantitative yield. This material then underwent
iteration from the reducing terminus using acceptor 61 to
produce hexasaccharide 62b in 86% yield. A final lactone
opening and protection step afforded 63b in 91% yield
(Scheme 12).
3.2.2. Synthesis of Heparin-Related [4]n Oligosaccharides
up to 40-Mer
In 2015 Gardiner and colleagues described the chemical
synthesis of the longest heparin-related oligosaccharide to date
(20-mer) using iterative synthesis and accessed protected
oligosaccharides ranging from 16-mer through to the 40-
mer.[37] Tetrasaccharide donor 64 was utitised in a coupling–
deprotection cycle of 2-step homologation reactions, yielding
oligosaccharides of increasing [4]n chain length (Scheme 13).
The synthesis initiated from O4-protected 12-mer 65[38] and,
following selective deprotection at O4, generated 12-mer
acceptor 66 in excellent yield. The subsequent homologation
to 16-mer and thence to 20-mer proceeded in very good
overall yield (68% and 79% respectively) for each 2-step
coupling/deprotection sequence. Glycosylations of increasingly
long acceptors with donor 64 proved reliable throughout a
series of [4]n iterations and afforded 24-mer, 28-mer, 32-mer,
36-mer and 40-mer materials. Oligosaccharide 69a was
deprotected and O-/N-sulfated to afford heparin-like 20-mer
70.
3.2.3. Exploring Functional Capability of Non-Reducing
End D-GlcN Residues within HS Sequences
Gardiner’s group also described installation of a non-reducing
O4 handle in order to introduce conjugation-suitable, terminal
functionality to biologically important HS oligosaccharides
(Figure 2).[39] Their approach introduced a d-GlcN O4-
aldehyde-level bearing unit (using an appropriate disaccharide
donor) to remain latent throughout oligosaccharide synthesis.
This latent aldehyde tag (LAT) was set to be unmasked at the
final stage of synthesis, yielding fully sulfated, heparin-type
Scheme 12. Reagents and conditions: (a) NIS, AgOTf, toluene, 60 precursor: 74%, 61 precursor: 87%; (b) NaOMe, MeOH, CH2Cl2; (c) BzCl, 1-
methylimidazole, DMAP, 1,2-DCE, 60: 90% 2 steps, 63a: 97% 2 steps, 63b: 91%, 2 steps; (d) Pyridine, MeOH, 61: 77%; (e) NIS, AgOTf, CH2Cl2, 62a:
85%, 62b: 86%.
Figure 2. Gardiner’s non-reducing end LAT technology, providing conjuga-
tion capability for HS oligosaccharides.
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oligosaccharides with non-reducing end functional capability.
This compared to an earlier, reducing end LAT unit
introduced by the group to enable radiolabelled HS dodeca-
saccharide synthesis.[38]
The effect of moderating reducing end d-GlcN sulfation
pattern was also investigated by the group.[40] Access to
scalable, iterative synthesis delivered a site specifically O6
sulfated dodecasaccharide, which was used in conjunction with
an earlier reported lower sulfated variant,[27] to then interrogate
the effects of both level and site specificity of defined sulfation
towards HS-dependant cytokines in vitro and in vivo .[40]
3.2.4. Modular Synthesis of HS Tetrasaccharide Libraries
To broadly explore HS-protein binding, Boons and co-
workers’ developed a library of 47 HS oligosaccharides for
microarray immobilisation and screening.[41] The design
conceived a limited number of tetrasaccharides which could be
regioselectively O- and N-sulfated to rapidly diversify the final
library. A total of 9 tetrasaccharides having 4 different
backbone compositions with varying protecting group patterns
were synthesised (Scheme 14A). With these in hand, regiose-
lective O-sulfations were completed, giving access to materials
of type 82 and 83 (Scheme 14B). Here the 6-OH at the distal
d-GlcN3 residue was found to be more reactive towards
sulfation than the proximal d-GlcN3 residue (82, 48% versus
83, 35%). Regioselective sulfate ester removal was also
explored using N,O-bis(trimethylsilyl)acetamide (BTSA) in
pyridine. This gave access to 85 and 86, where the 6-O-sulfate
at the proximal d-GlcN3 residue was more susceptible to
hydrolysis than the distal position (85, 50% versus 86, 27%).
Similar diversification from tetrasaccharides 75, 77 and 80
(with alternate backbone compositions) afforded an additional
19 sulfated oligosaccharides. Conventional modifications of
tetrasaccharides 72–74, 76 and 79 gave an additional 5
Scheme 13. Gardiner’s HS 20-mer and protected 40-mer synthesis: Reagents and conditions: (a) MeOH, pyridine, 66: 93%, 68a: 90%, 68b: 97%, 68c: 95%,
68d: 93%, 68e: 93%, 68f: 87%; (b) NIS, AgOTf (cat.), DCM, 64, 67: 76%, 69a: 81%, 69b: 77%, 69c: 75%, 69d: 78%, 69e: 72%, 69f: 64%.
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oligosaccharides that had lower levels of sulfation or possessed
differently modified amino groups.
The group also recently reported an integrated method-
ology to broadly determine the ligand requirements of HS-
binding proteins.[42] This involved firstly completing partial
degradation of natural HS, followed by fragment screening
against an immobilised HS-binding protein. Compositional
analysis using HILIC-HRMS identified moderately sulfated
octasaccharide sequences that informed subsequent chemical
synthesis of a structurally defined ligand for further structure
activity studies. This workflow was demonstrated successfully
to establish the ligand requirements of the human Roundabout
receptor 1 (Robo 1).
3.2.5. Access to a Sulfonamide-Containing HS Fragment
Hung and co-workers’ examined the effectiveness of substrates
and inhibitors of human endo-O-sulfatase-1 (Scheme 15).[43]
The team synthesised a range of HS oligosaccharides with
various chain lengths and N- and O- sulfation patterns and
studied their substrate and inhibitor specificity using a
competitive fluorogenic substrate, 4-methylumbelliferyl sulfate
(4-MUS).
Scheme 14. A) Tetrasaccharide building blocks. B) Diversification example of tetrasaccharide 78 into 12 HS oligosaccharides. Reagents and conditions:
(a) (i) Et3N, MeOH, DCM; (ii) Ac2O, pyridine, DMAP; (iii) NH2NH2 ·AcOH, DCM, MeOH, rt, 2 h, 77%, 3 steps; (b) SO3 ·pyridine, DMF, 2 h, 81%;
(c) (i) LiOH, H2O2, THF, 4 h, then NaOH, MeOH, 12 h; (ii) PMe3, THF, MeOH, NaOH, 1 h, 87: 78%, 88: 54%, 89: 70%, 90: 67%, 91: 54%;
(d) (i) Ac2O, MeOH, Et3N; (ii) Pd/C, H2, MeOH, H2O, 4 h; (iii) Pd(OH)2, H2, H2O, 14 h, 92: 65%, 94: 72%, 96: 85%, 98: 77%, 100: 72%, 104: 82%;
(e) (i) SO3 ·pyridine, MeOH, Et3N, NaOH, 12 h; (ii) Pd/C, H2, MeOH, H2O, 4 h; (iii) Pd(OH)2, H2, H2O, 14 h, 93: 68%, 95: 77%, 97: 67%, 99: 69%,
101: 77%, 105: 71%; (f) BTSA, pyridine, 60 °C, 2 h, 85: 50%; 86: 27%; (g) SO3 ·pyridine, DMF, 83: 35%, 87: 48%; (h) LiOH, H2O2, THF, 4 h, then
NaOH, MeOH, 12 h, 84%; (i) PMe3, THF, MeOH, NaOH, 1 h, 87%; Ra=(CH2)5NBnCbz; Rb=(CH2)2NH2.
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To synthesise trisaccharides 113a and 113b, l-ido donor
106 and disaccharide acceptor 107 were glycosylated using
NIS and TfOH to furnish α-linked trisaccharide 108.
Sequential deacylation using Zemplén’s conditions and TEM-
PO oxidation converted 108 to lactone 109. Ring opening of
109 delivered methyl ester 110 which was subjected to O-
sulfation to yield a bis-O-sulfated derivative 111. Desilylation
and treatment with either SO3 ·Et3N or ClSO2NHBn,
converted 111 to the sulfate 112a or sulfonamide 112b.
Following final deprotections, target trisaccharides 113a and
113b were accessed in 11 and 5% overall yields respectively
and in 11 steps.
3.3. O- and N-Sulfation Methods
3.3.1. Synthetic HS Sequences Containing GlcNAc and
GlcNS
In 2020 Boons and colleagues presented a modular approach
to access HS oligosaccharides containing both d-GlcNAc and
d-GlcNS units.[44] A previous modular synthetic route from
the group provided a diverse range of HS oligosaccharides
from two common disaccharide building blocks, 114 and 115
(Scheme 16A),[45] but did not deliver sequences containing
both d-GlcNS and d-GlcNAc.
To address this (ultimately, to mimic high and low N-
sulfation HS domains) the group synthesised a new pair of
disaccharide building blocks 116a and 116b (Scheme 16A).
Nguyen and co-workers’ had established that α-glycosides were
selectively formed using a Ni(II) triflate promoted activation
of glycosyl donors containing the C2-trifluorometh-
ylphenylmethanimine moiety present in 116a and 116b.[46]
This, alongside the possibility for its orthogonal removal under
mild acidic conditions, presented the prospect to build d-
GlcN-azide and d-GlcN-imine containing oligosaccharides.
Accordingly, optimal conditions for the preparation of
tetrasaccharide 118a from donor 116a and acceptor 117
(Scheme 16B) were established. This afforded the α-anomer of
118a in an acceptable 58% yield. Scheme 16B also illustrates
the subsequent conversion of 118a into a final tetrasaccharide
119, containing both d-GlcNS and d-GlcNAc components.
Finally, the team were able to assemble hexasaccharides
120a–d (Figure 3) in good yields from modular disaccharide
donors and conventional acceptors via a series of sequential
Scheme 15. Hung and co-workers’ synthesis of 113a–b to elucidate substrate specificity for Sulf-1. Reagents and conditions: (a) NIS, TfOH, CH2Cl2,   78 to
  40 °C, 4 h, 82%; (b) (i) NaOMe, CH2Cl2, MeOH (1 :1), rt, 18 h; (ii) TEMPO, BAIB, H2O, CH2Cl2 (1 : 2), rt, 16 h, 70%, 2 steps; (c) MeOH, Et3N, CH2Cl2,
40 °C, 18 h, 89%; (d) SO3 ·Et3N, DMF, 60 °C, 18 h, 79%; (e) (i) HF ·pyridine, pyridine, THF, 72 h; (ii) SO3 ·Et3N, DMF, 60 °C, 18 h, 112a: 73%, 2 steps;
(f) (i) HF ·pyridine, pyridine, THF, 72 h; (ii) ClSO2NHBn, pyridine, rt, 10 min., 112b: 83%, 2 steps; (g) (i) LiOH, H2O2, THF, 37 °C, 18 h; (ii) PMe3, THF,
THF, NaOH, rt, 14 h; (iii) SO3 ·pyridine, Et3N, NaOH, MeOH, rt, 18 h; (iv) Pd(OH)2/C, H2, MeOH, pH 7, rt, 3 d, 113a: 38%, 4 steps, 113b: 14%,
4 steps.
Figure 3. Hexasaccharides 120a–d.
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deprotection and sulfation steps. To study the effects of NS
versus NAc substitution and sulfation pattern, compounds
120a–d, were printed as a glycan microarray onto an N-
hydroxysuccinamide activated glass slide and their binding to
chemokines IL-8 and RANTES were investigated. Studies
revealed that IL-8 was able to bind a hexasaccharide in which
d-GlcNS was replaced by d-GlcNAc units (120d versus
120b); moreover absence of 6-OS caused a reduction in
binding (120d versus 120c).
3.3.2. Methodology Improvements to Effect O and
N-Sulfation
Yu and co-workers’ reported an effective method to simulta-
neously complete O- and N-sulfation under microwave
conditions (Scheme 17).[47] Using a cocktail of SO3 ·Et3N,
NEt3 and pyridine, a simultaneous O,N-sulfation could be
completed in a very short time (15 minutes). In the absence of
NEt3 only O-sulfation took place; hence, the presence of NEt3
was deemed crucial to obtain simultaneous heteroatom
sulfation. Interestingly, using the same cocktail with conven-
tional heating gave only N-sulfation. A rationale for these
observations was that as O-sulfonation occured, the system
became acidic, leading to protonation of the amino group
which was then not free to react with sulfur trioxide. However,
the presence of NEt3 deprotonates the hexosamine nitrogen,
thus enabling N-sulfation. The reaction conditions worked
well on a range of mono-, di-, tri- and tetrasaccharides
(>90% yields) and sterically hindered hydroxyl groups
(121a) were sulfated without issue.
In 2020, Niu and co-workers’ reported an approach to
early stage O-sulfation via the sulfur(VI) fluoride exchange
(SuFEx) reaction between TMS-protected sugars and aryl
fluorosulfates (Scheme 18).[48] Arylfluorosulfates bearing elec-
tron withdrawing substituents worked best for sulfate diester
formation. The authors also demonstrated a one-pot, in-situ
hydroxyl silylation with hexamethyldisilazane (HMDS) and
subsequent SuFEx reaction. This one-pot protocol is useful as
it circumvents any need to purify intermediate TMS silyl-
ethers, which are known to be unstable on silica. The sulfate
diesters showed excellent robustness to subsequent acidic,
basic, oxidising and reducing reaction conditions. Various
glycosyl donors and acceptors decorated with sulfate diesters
were successfully employed for glycosylation reactions. Sulfate
diester deprotection was achieved using late-stage hydro-
genolysis. This early-stage O-sulfation method provides a
Scheme 16. A) Boon’s modular disaccharide building blocks B) Glycosidation of trifluoro-N-phenylacetimidate disaccharides. Reagents and conditions:
(a) TfOH,   20 °C, 12 h, 58%; (b) Pd(PPh3)4, THF, H2O, 2 h; (c) HCl, THF, H2O, 15 min., then Ac2O, pyridine, 3 h, 90%, 2 steps; (d) NH2NH2 ·AcOH,
toluene, EtOH, 2 h; (e) SO3 ·pyridine, DMF, 2 h; (f) LiOH, H2O2, THF, H2O, 60%, 5 steps; (g) PMe3, NaOH, THF, H2O, 2 h; (h) SO3 ·pyridine, MeOH,
Et3N, 66%, 2 steps; (i) Pd(OH)2/C, H2, tBuOH, H2O, 24 h, 90%.
Scheme 17. Microwave assisted simultaneous O- and N-sulfation by Yu and
co-workers’.[47]
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general, powerful tool for the synthesis of O-sulfated bioactive
compounds.
4. Automated and Solid Phase Synthesis
Approaches to HS Sequences
4.1 Solid Phase Synthesis of a H/HS Hexasaccharide
Precursor
The solid-phase synthesis (SPS) of carbohydrate targets is
renowned for its challenges in comparison to solution-phase
approaches. Unlike automated peptide and oligonucleotide
assembly, oligosaccharide synthesis requires the development
of procedures to account for multiple hydroxyl groups of
similar reactivity and the requirement for high yielding and
stereoselective glycosylation reactions. In 2015, Reichardt and
co-workers’ developed an effective strategy in this area for the
solid-phase assembly of an HS precursor using monosaccharide
building blocks (Scheme 19).[49]
Previous work by the group established that monosacchar-
ide 123a had good reactivity and stability for the solid-phase
synthesis of a HS trisaccharide precursor.[50] Therefrom, the
sequential assembly of a hexasaccharide was performed using
monosaccharides 123a–d. Attachment of a pentyl spacer unit,
protected with a 4-hydroxymethylbenzyl N-benzyl carbamate,
to a carboxystyrene resin via an ester linkage provided a
reliable solid-support (122). Successive capping, delevulination
of idose-O4 and alternate glycosylation cycles with donors
123a, 123b and 123c, followed by final glycosylation with d-
GlcN donor 123d furnished H/HS precursor 124a, after
cleavage from the resin. Acetylation of this material and HPLC
purification gave the desired hexasaccharide 124b in an 11%
yield over 14 steps (85% average yield per step). This effective
method delivered significant progress towards a routine and
automatable solid-phase approach, notably completable within
2–3 weeks, as opposed to several months in solution phase.
4.2 Automated Glycan Assembly of H/HS
An alternative approach towards an HS hexasaccharide
precursor was reported by Fascione and Schwörer using
automated glycan assembly (AGA) (Scheme 20).[51] AGA
eliminates the reliance on manual methods (chemoenzymatic,
solution-phase and solid-phase) and provides a rapid approach
towards the formation of biologically important carbohydrates.
The team reported iterative, automated solid-phase synthesis
of an HS hexasaccharide precursor using Glyconeer™, the
automated oligosaccharide synthesiser.
Disaccharide 125a was employed as the initial donor
towards the synthesis of hexasaccharide 127. A labile Fmoc
protecting group was used as the temporary protecting group
Scheme 18. Niu and co-workers’ early-stage O-sulfation using SuFEx chemistry.
Scheme 19. Solid-phase assembly of a H/HS hexasaccharide precursor by Reichardt and co-workers’. Reagents and conditions: (a) NIS, TMSOTf,   20 °C to rt;
(b) NH2NH2 ·AcOH, DCM, MeOH (4 :1); (c) NaOMe, MeOH; (d) Ac2O, pyridine, 0 °C to rt.
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at O-4, to release acceptor capability for d-GlcN for chain
elongation throughout the iterative glycosylations. Fmoc
deprotection could be conveniently monitored by an inline
UV detector, which measured the amount of dibenzofulvene
adduct released in solution. A Merrifield resin was chosen as
the solid-support and this was additionally functionalised with
a photolabile nitrobenzyl ether-based linker (stable to acidic
and basic reaction solutions). Excess hydrolysed donor 126a
from glycosylation steps was recycled back to 125a in solution,
at an efficiency of ~60%, highlighting the resourcefulness of
AGA. Finally, cleavage from the resin was performed using an
in house photoreactor, followed by filtration and evaporation
to afford the crude hexasaccharide. Purification via silica gel
flash column chromatography afforded 127 in 6 hours with a
30% yield on 15 mg scale.
Interestingly, this approach proposed to complete a late-
stage oxidation of d-Glc to d-GlcA (after oligosaccharide
assembly) and a recent report from Schwörer has indeed
highlighted the need for consideration of the complimentarity
of this approach versus using d-GlcA disaccharide donors
directly.[52]
5. Conclusion and Outlook
Developments in the field of chemical H/HS synthesis over
the past five years have largely focused around and achieved
the provision of ever longer and more diverse libraries of
sulfation variant ligands. This has been expedited by improve-
ments in access to requisite building blocks, notably introduc-
ing an upcycling of HS-related polysaccharides to deliver such
materials. The matrix of structural possibilities for HS is
enormous and often daunting, but the advent of integrated
platforms to guide ligand design (and therefore synthesis) will
certainly simplify future endeavours here.
Technologies to synthesise these essential glycan fragments
have also undergone improvements. From the perspective of
medically relevant heparin sequences, iterative, programmable,
one-pot solution-phase syntheses to access defined fragment
lengths surrounding Fondaparinux have emerged. Coupled
with the recent establishments of automated glycan assembly
and traditional solid phase synthesis, it is likely that there will
be easier and more rapid access to ever more diverse and
challenging sequences to support biological requirements in
the near future. This must of course be considered in tandem
and synergise with achievements made in the chemoenzymatic
preparation of H/HS.
An additional area that will surely continue to grow as a
result of these accomplishments is around the fusion of HS
synthesis with protein conjugation/synthesis, which will enable
study of the larger and more challenging HS-proteoglycan axis.
Such endeavours were recently exemplified through the syn-
thesis and evaluation of a human syndecan-4
glycopeptide.[53,54]
Scheme 20. Fascione and Schwörer’s AGA of an HS hexasaccharide precursor.
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